NDC Pharmacologic Class N0000175657 CD20-directed Cytolytic Antibody [EPC]
NDC | Proprietary Name | Non-Proprietary Name | Dosage Form | Route Name | Company Name | Product Type |
---|---|---|---|---|---|---|
0069-0238 | Ruxience | Rituximab-pvvr | Injection, Solution | Intravenous | Pfizer Laboratories Div Pfizer Inc | Human Prescription Drug |
0069-0249 | Ruxience | Rituximab-pvvr | Injection, Solution | Intravenous | Pfizer Laboratories Div Pfizer Inc | Human Prescription Drug |
0078-0669 | Arzerra | Ofatumumab | Injection, Solution | Intravenous | Novartis Pharmaceuticals Corporation | Human Prescription Drug |
0078-0690 | Arzerra | Ofatumumab | Injection, Solution | Intravenous | Novartis Pharmaceuticals Corporation | Human Prescription Drug |
0078-1007 | Kesimpta | Ofatumumab | Injection, Solution | Subcutaneous | Novartis Pharmaceuticals Corporation | Human Prescription Drug |
50242-051 | Rituxan | Rituximab | Injection, Solution | Intravenous | Genentech, Inc. | Human Prescription Drug |
50242-053 | Rituxan | Rituximab | Injection, Solution | Intravenous | Genentech, Inc. | Human Prescription Drug |
50242-070 | Gazyva | Obinutuzumab | Injection, Solution, Concentrate | Intravenous | Genentech, Inc. | Human Prescription Drug |
50242-108 | Rituxan Hycela | Rituximab And Hyaluronidase | Injection, Solution | Subcutaneous | Genentech, Inc. | Human Prescription Drug |
50242-109 | Rituxan Hycela | Rituximab And Hyaluronidase | Injection, Solution | Subcutaneous | Genentech, Inc. | Human Prescription Drug |
50242-150 | Ocrevus | Ocrelizumab | Injection | Intravenous | Genentech, Inc. | Human Prescription Drug |
55513-224 | Riabni | Rituximab-arrx | Injection, Solution | Intravenous | Amgen Inc | Human Prescription Drug |
55513-326 | Riabni | Rituximab-arrx | Injection, Solution | Intravenous | Amgen Inc | Human Prescription Drug |
63459-103 | Truxima | Rituximab-abbs | Injection, Solution | Intravenous | Cephalon, Inc. | Human Prescription Drug |
63459-104 | Truxima | Rituximab-abbs | Injection, Solution | Intravenous | Cephalon, Inc. | Human Prescription Drug |
There are 15 NDC products with the pharmacologic class CD20-directed Cytolytic Antibody [EPC].